New therapy wipes out cervical cancer in two women

June 2, 2014 by Kerry Sheridan
High grade dysplasia (carcinoma in situ) in the uterine cervix. The abnormal epithelium is extending into a mucus gland to the left of centre. This disease can progress to invasive cancer (squamous cell carcinoma) of the cervix. Credit: Haymanj/public domain

Aricca Wallace knew she was nearly out of time. For more than three years, she had suffered cramping and irregular bleeding, which her doctor thought was a side effect of her birth control implant, known as an intrauterine device, or IUD.

Her annual Pap smears were always normal, so no one suspected cancer.

Except it was cancer, and by the time the 34-year-old mother of two had the IUD removed and was finally diagnosed, her tumors had reached stage three and the disease was spreading through the lymph nodes in her abdomen and chest.

"I was told by a specialist that there wasn't any chemo that could kill it," Wallace told AFP. "And that I'd be gone in a year."

That was in February 2012. A few months later, Wallace's doctor told her about an immunotherapy trial at the National Institutes of Health Clinical Center, a research hospital just outside the US capital.

Wallace enrolled. Doctors removed one of her tumors and collected some of the that were surrounding it. They selected specific T-cells that would attack human papillomavirus.

HPV is a common sexually transmitted disease, and most adults get it at some point in their lives. While HPV is often harmless, some strains can cause genital warts or lead to cancers of the cervix, anus, head, neck and throat.

Some 70 percent of cervical cancers are caused by HPV types 16 and 18.

The idea behind HPV-targeted adoptive T-cell therapy is to boost the body's immune response to HPV in the tumors.

Worst fever ever

Wallace first endured a week-long regimen of strong chemotherapy to knock out her immune system. Then came the infusion, which aimed to rebuild her defenses with more than 100 billion of her lab-grown T-cells that targeted the tumors.

After that, she was given two doses of aldesleukin, which helps the immune cells grow.

The treatment can lead to serious side effects like bleeding, vomiting, low blood pressure, fluid retention, confusion, fever and infection.

"It was the worst fever I ever had," recalled Wallace.

But it worked. Her tumors grew steadily smaller. Four months after the infusion, all the tumors were gone.

On May 29, Wallace visited the NIH Clinical Center again for scans, which showed no disease, marking 22 months since the start of her experimental treatment.

"It is a miracle, honestly," said Wallace, now 37.

Immunotherapy is a promising field that has shown some early successes against the deadly skin cancer melanoma and a handful of other cancers.

Wallace is the first person with cervical cancer on whom this novel approach has worked.

A second US woman has also seen her metastatic disappear completely and is still disease-free one year later.

Two of nine patients

But they are just two of nine patients in total. A third woman responded for a short time, but then her cancer returned. The treatment did not help the other six women in the study.

"With only nine patients, we can't even say with any reliability how well it works," said Christian Hinrichs, Assistant Clinical Investigator at the National Cancer Institute.

"All we know is that it can work," added Hinrichs, who presented his research to reporters on Monday at the American Society for Clinical Oncology annual meeting in Chicago.

The technique is based on a state-of-the-art personalized medicine approach developed by his boss, Steven Rosenberg at the National Cancer Institute, to expand tumor infiltrating lymphocytes against metastatic melanoma.

Hundreds of cancer patients have been treated with some kind of adoptive T-cell therapy, or ACT, but success rates have varied widely.

Some 40 percent of patients with who underwent the process are showing no signs of cancer after seven years, according to research published late in 2013.

The technique is still a long way from becoming everyday practice in medicine, and researchers have yet to figure out why it works in some but not in others.

"With the refinement of adoptive T-cell therapy and reduction of potential significant side effects, this can offer hope for improvement of survival for patients with advanced cervical cancers," said Linus Chang, professor of obstetrics and gynecology at Icahn School of Medicine at Mount Sinai. Chang was not involved in the study.

Cervical infects some 530,000 women each year and kills more than 270,000 around the globe, with most deaths occurring in the developing world, according to the World Health Organization.

Despite the rapid and complete responses that two of his patients have seen, Hinrichs said it is far too early to declare them cured.

But Wallace said she does not care about the terminology.

"You can't argue with the scans," she told AFP.

"It's not there and I feel good. I don't have to hear the word 'cure.'"

Explore further: One woman's cancer battle highlights promise of new treatment

Related Stories

One woman's cancer battle highlights promise of new treatment

May 8, 2014
Just over two years ago, Melinda Bachini decided she was done with chemotherapy to treat her cholangiocarcinoma—a rare cancer of the bile duct that runs from the liver to the intestines.

FDA experts debate timing of pap test

March 12, 2014
(HealthDay)—The Pap test has been a routine gynecological procedure for generations of American women. But on Wednesday, a Food and Drug Administration advisory panel is considering whether to delay the Pap test and use ...

Number of cancer stem cells might not predict outcome in HPV-related oral cancers

January 22, 2014
(Medical Xpress)—New research from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) suggests that it may be the quality ...

Genetic testing beneficial in melanoma treatment

April 4, 2014
(Medical Xpress)—Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University ...

Immune therapy for advanced bladder cancer yields promising results

May 31, 2014
A multi-center phase I study using an investigational drug for advanced bladder cancer patients who did not respond to other treatments has shown promising results in patients with certain tumor types, researchers report. ...

Moffitt Cancer Center begins Phase I clinical trial of new immunotherapy

April 10, 2014
Moffitt Cancer Center has initiated a phase I clinical trial for a new immunotherapy drug, ID-G305, made by Immune Design. Immunotherapy is a treatment option that uses a person's own immune system to fight cancer. It has ...

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.